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A B S T R A C TObjectives: This is the first study to compare the incidence and
health care costs of medically attended adverse effects in atazanavir-
and darunavir-based antiretroviral therapy (ART) among U.S. Medicaid
patients receiving routine HIV care. Methods: This was a retrospec-
tive study using Medicaid administrative health care claims from 15
states. Subjects were HIV patients aged 18 to 64 years initiating
atazanavir- or darunavir-based ART from January 1, 2003, to July 1,
2010, with continuous enrollment for 6 months before (baseline) and 6
months after (evaluation period) ART initiation and 1 or more evalua-
tion period medical claim. Outcomes were incidence and health care
costs of the following medically attended (International Classification of
Diseases, Ninth Revision, Clinical Modification–coded or treated) adverse
effects during the evaluation period: gastrointestinal, lipid abnormal-
ities, diabetes/hyperglycemia, rash, and jaundice. All-cause health
care costs were also determined. Patients treated with atazanavir
and darunavir were propensity score matched (ratio ¼ 3:1) by
using demographic and clinical covariates. Multivariable models
adjusted for covariates lacking postmatch statistical balance. Results:
Propensity-matched study sample included 1848 atazanavir- and 616see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.10.021
johnston@truvenhealth.com.
ondence to: Stephen S. Johnston, 4301 Connecticutdarunavir-treated patients (mean age 41 years, 50% women, 69%
black). Multivariable-adjusted hazard ratios (HRs) (for darunavir, refer-
ence ¼ atazanavir) and per-patient-per-month health care cost differ-
ences (darunavir minus atazanavir) were as follows: gastrointestinal,
HR ¼ 1.25 (P ¼ 0.04), $43 (P ¼ 0.13); lipid abnormalities, HR ¼ 1.38 (P ¼
0.07), $3 (P ¼ 0.88); diabetes/hyperglycemia, HR ¼ 0.84 (P ¼ 0.55), $13
(P ¼ 0.69); and rash, HR ¼ 1.11 (P ¼ 0.23), $0 (P ¼ 0.76); all-cause health
care costs were $1086 (Po 0.001). Too few instances of jaundice (11 in
atazanavir and 1 in darunavir) occurred to support multivariable
modeling. Conclusions: Medication tolerability can be critical to the
success or failure of ART. Compared with darunavir-treated patients,
atazanavir-treated patients had significantly fewer instances of medi-
cally attended gastrointestinal issues and more instances of jaundice
and incurred significantly lower health care costs.
Keywords: adverse effects, antiretroviral therapy, atazanavir, darunavir,
health care costs, Medicaid.
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Antiretroviral therapy (ART) adverse effects can have a substan-
tial impact on patients’ quality of life, health care resource
utilization, and adherence and persistence to therapy [1–4]. Poor
ART adherence and discontinuation can result in viral rebound,
immune decompensation, and clinical progression. It can also
result in the development of drug-resistant virus, which, in turn,
can result in the permanent loss of therapeutic options [1,5,6].
Owing to their benefits of optimal and durable virologic
efficacy, ease of use, and favorable tolerability and toxicity
profiles, atazanavir and darunavir are currently the only protease
inhibitors (PIs) that are designated as preferred for first-line ART
regimens in the Department of Health and Human Services
antiretroviral treatment guidelines [1]. Furthermore, atazanavir
and darunavir may also be used as options after the initial failure
of a first-line ART regimen [7]. The U.S. Food and Drug Adminis-
tration approved atazanavir in 2003 and darunavir in 2006.PIs have been shown to be associated with a variety of adverse
effects, including gastrointestinal intolerance, insulin resistance,
hepatotoxicity, dyslipidemia, and rash [1,8–10]. Although the
common adverse effects of PIs as a class have been established,
the current understanding of the variation in adverse effects
across specific PIs is based on findings from completed clinical
trials, none of which have directly compared darunavir with
atazanavir.
ACTG 5257 is a fully enrolled, prospective, randomized trial
comparing efficacy and safety in ritonavir-boosted atazanavir þ
emtricitabine/tenofovir disoproxil fumarate, ritonavir-darunavir
þ emtricitabine/tenofovir disoproxil fumarate, and raltegravir þ
emtricitabine/tenofovir disoproxil fumarate for treatment-naive
HIV-1–infected volunteers [11]. However, because the results of
this trial are not expected until late 2013 or 2014, other sources of
data, such as administrative claims, are required to conduct
research that compares atazanavir- and darunavir-based ART.
Findings from such ‘‘real-world’’ data sources can complementSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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trials because they can offer broad generalizability and provide
detailed information on health care costs associated with adverse
effect and other forms of medical care that are often not collected
in a systematic way within trials.
In the current study, we used real-world data to compare the
incidence and health care costs of medically attended (Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modifi-
cation [ICD-9-CM]-coded or treated) adverse effects in atazanavir-
and darunavir-based ART among U.S. Medicaid patients receiving
routine HIV care.Methods
Study Design and Data
This study used a retrospective, observational design with pro-
pensity score matching and multivariable statistical analysis
techniques. Five specific adverse effects, adapted from those
listed within the Department of Health and Human Services
treatment guidelines for antiretroviral agents as being common
in atazanavir or darunavir, were chosen for study [1]. These were
gastrointestinal, lipid abnormalities, diabetes/hyperglycemia,
rash, and jaundice.
The data studied were administrative health care claims for
Medicaid patients extracted from the 2002 to 2010 years of the
Truven Health Analytics MarketScan Multi-State Medicaid (Med-
icaid) Database. This population was chosen because the Medi-
caid program covers an estimated 38% to 42% of HIV patients
receiving care, making it the single largest source of health
insurance for people living with HIV in the United States
[12,13]. The Medicaid database comprises inpatient medical,
outpatient medical, and outpatient prescription claims and
encounter records collected from among patients from 15 geo-
graphically dispersed Medicaid states that vary in size and
sociodemographic composition. These claims are coded with
ICD-9-CM, Current Procedural Terminology, National Drug, and
Healthcare Common Procedure Coding System codes, which are
the current coding standards in the United States. Because of
confidentiality agreements between Truven Health Analytics and
the states that contribute their data to the Medicaid database,
further public disclosure of identifying information about the
state Medicaid programs is restricted. The data contained in the
Medicaid database are statistically de-identified and fully com-
pliant with the Health Insurance Portability and Accountability
Act Privacy Regulations; as such, institutional review board
approval and written informed consent were not sought for
this study.
Sample Selection Criteria
Patients selected for study were required to have initiated an ART
regimen between January 1, 2003, and January 1, 2010, comprising
at least two nucleoside reverse transcriptase inhibitors (NRTIs:
abacavir, didanosine, emtricitabine, lamivudine, stavudine,
tenofovir, zidovudine, zalcitabine, abacavir/lamivudine, emtrici-
tabine/tenofovir DF, zidovudine/lamivudine, zidovudine/lamivudine/
abacavir) in combination with either atazanavir or darunavir,
with or without ritonavir boosting; patients with prescription
claims for ART prior to initiating atazanavir or darunavir
were allowed to enter the study. The study index date was
defined as the first observed prescription claim for atazanavir or
darunavir.
Patients were required to be aged 18 to 64 years on the index
date and have continuous Medicaid enrollment for 6 months
before the index date (designated the baseline period) and for 6months after the index date. Patients were also required to have
at least one medical claim during the 6-month period of con-
tinuous Medicaid enrollment after the index date to ensure that
they had maintained contact with the health care system and
thus medically attended adverse effects could be observed.
Patients who had separate episodes of treatment with ataza-
navir and darunavir, and for whom all study inclusion criteria
were met at the time when they initiated each drug, contributed
two separate observations to the study analysis, one for the time
covered by atazanavir and one for the time covered by darunavir;
this was the case for 78 unique patients. Consequently, the study
analyses were conducted on an ‘‘episode of treatment’’ unit of
observation.
Evaluation Period and Outcomes
The study evaluation period, defined in detail below, was used to
measure the incidence and health care costs of medically
attended adverse effects as well as all-cause health care costs.
All-cause health care costs were defined as health care costs
incurred for all inpatient medical, outpatient medical, and out-
patient prescription claims during the evaluation period and are
not limited to medically attended adverse effects.
Research indicates that PI-related adverse effects frequently
occur within the first 3 to 4 months of PI initiation [9,10,14,15].
Accordingly, to capture the majority of adverse effects, the
evaluation period was constructed to begin on the index date
and end with censoring at the earliest occurrence of either 6
months after the index date or the addition of a different critical
agent (PI, non-NRTI, fusion inhibitor, or integrase inhibitor)
within the initiated ART regimen. Among the darunavir-treated
patients, 78 (12.7%) were coadministered etravirine and 138
(21.8%) were coadministered raltegravir, with coadministration
of these drugs being observed almost exclusively in individuals
who had claims for ART prior to their index date, suggesting ART
experience. Therefore, to allow for such instances of real-world
prescribing patterns to be reflected within the study, patients
who initiated either of these agents with darunavir were not
excluded from the study.
Table 1 presents the algorithms, codes, and medication classes
used for measuring the five specific adverse effects chosen for this
study. Health care costs were summarized as per-patient-per-
month (PPPM) units to account for across-patient variability in the
duration of the evaluation period and were expressed in 2010
constant dollars, adjusted by using the Medical Care component
of the consumer price index [16]. The incidence rates of medically
attended adverse effects were calculated as the number of
patients with a specific medically attended adverse effect divided
by the sum of person-time observed for each patient, where
person-time was calculated as the duration of time from the
index date until the date of occurrence of the medically attended
adverse effect or censoring at the end of the evaluation period.
Covariates
Covariates included patient demographics and clinical character-
istics. Patient demographics were defined at the index date and
included age, sex, race/ethnicity (black, Hispanic, white, other),
insurance plan type (comprehensive, health maintenance orga-
nization, preferred provider organization, point of service, point
of service with capitation, unknown), index year, urban versus
rural residence, and the Medicaid state from which the patient
was identified. Clinical characteristics included ART experience
(defined as having baseline prescription claims for ART; patients
without baseline prescriptions for ART were designated ART
naive), presence of ritonavir boosting within the ART regimen at
index, NRTIs included within the ART regimen at index, proxy
Table 1 – Algorithms, codes, and medication classes used for measuring medically attended (ICD-9-CM–coded
or treated) adverse effects.
Adverse effect Algorithm ICD-9-CM Medication classes
Gastrointestinal
symptoms
One inpatient or one
nondiagnostic outpatient claim
with an ICD-9-CM diagnosis code
for diarrhea, nausea, or vomiting
OR by at least one outpatient
pharmaceutical prescription
claim for an antiemetic or an
antidiarrhea agent
787.01,
787.02,
787.91
Antiemetics, antidiarrhea agents
Jaundice One inpatient or one
nondiagnostic outpatient claim
with an ICD-9-CM diagnosis code
for jaundice
782.4x None
Lipid abnormalities One inpatient or one
nondiagnostic outpatient claim
with an ICD-9-CM diagnosis code
for dyslipidemia OR at least one
outpatient pharmaceutical
prescription claim for a lipid-
lowering therapy
272.0, 272.1, 272.2, 272.3,
272.4
Bile-sequestering resins, statins,
niacin, and fibrates
Diabetes/hyperglycemia One inpatient or one
nondiagnostic outpatient claim
with an ICD-9-CM diagnosis code
for diabetes/hyperglycemia OR
at least one outpatient
pharmaceutical prescription
claim for an antidiabetic
medication
250.xx, 792.xx Alpha-glucosidase inhibitors,
biguanides, dipeptidyl
peptidase-4 inhibitors,
meglitinides, sulfonylureas,
thiazolidinediones, insulins,
glucagon-like peptide-1 analogs,
amylin analog
Rash One inpatient or one
nondiagnostic outpatient claim
with an ICD-9-CM diagnosis code
for rash OR at least one
outpatient pharmaceutical
prescription claim for a topical
glucocorticoid or calamine
692.3, 692.89, 692.9, 693.0,
693.9, 695.0, 695.1,
695.3
Topical glucocorticoids, calamine
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
* When measuring new-onset adverse effects, patients with baseline period evidence of a given chronic adverse effect (i.e., lipid abnormalities
or diabetes/hyperglycemia) were excluded from the calculation of incidence rates for that particular chronic adverse effect. For inpatient
claims, the entire cost associated with a claim was included if it had a primary diagnosis code indicative of the adverse effect. If an inpatient
claim had a relevant diagnosis code for an adverse effect in a nonprimary position, then only the costs for services associated with that
diagnosis code were included. For outpatient claims, the entire cost associated with a claim was included if any diagnosis code indicative of
the adverse effect was recorded on the claim.
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ICD-9-CM diagnosis codes, number of unique national drug
codes), baseline presence of diagnosed comorbid conditions
(hepatitis B, hepatitis C, alcohol or substance abuse, depression,
other psychiatric diagnoses), and the baseline presence of each
medically attended adverse effect.
Propensity Score Matching and Multivariable Statistical
Analyses
To construct atazanavir and darunavir cohorts that were
balanced with respect to the measured demographic and clinical
characteristics, atazanavir-treated patients were propensity score
matched at a 3:1 ratio to darunavir-treated patients. Because
patient experience with ART is likely to be strongly correlated
with study outcomes, the statistical approach was focused on
achieving balance on this covariate. After testing several
approaches, it was determined that the optimal balance on this
covariate could be achieved only when fitting propensity scoremodels that were stratified by ART experience. Accordingly, two
separate propensity score models were fitted: one subset to ART-
naive patients and one subset to ART-experienced patients. The
resulting matched samples were then combined for analysis.
In each of the two propensity score models, multivariable
logistic regression was used to predict the probability (i.e., the
propensity score) of being in the atazanavir versus darunavir
cohorts as a function of patient age, sex, race/ethnicity, insurance
plan type, index year, Medicaid state, proxy indices of baseline
health status, and baseline presence of diagnosed comorbid
conditions. The propensity scores were used to match the
atazanavir and darunavir cohorts through nearest neighbor
matching, without replacement, within a caliper of 0.25 SDs of
the propensity score.
Postmatch multivariable models were used to adjust for the
baseline presence of medically attended adverse effects and
covariates lacking postmatch statistical balance, as indicated by
a standardized difference value of greater than 10 [17]. Multi-
variable Cox proportional hazards models were used to analyze
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multivariable generalized linear model approach with a log link
and gamma error distribution was used to analyze health care
costs for all-cause and medically attended lipid abnormality
adverse effects. To handle distributions characterized by a large
concentration of 0 values, a two-part multivariable generalized
linear model approach, in which the first part modeled the
probability of incurring any health care costs for a given medi-
cally attended adverse effect and the second part modeled
differences in health care costs among those with nonzero costs,
was used to analyze health care costs for medically attended
gastrointestinal, diabetes/hyperglycemia, and rash adverse
effects. Finally, because patients who were treated with both
atazanavir and darunavir were allowed to contribute two obser-
vations to the data set, the Huber-White ‘‘sandwich’’ variance
estimator was used to calculate robust variances to address the
potential for clustering within the multivariable analyses [18].Sensitivity Analysis
Two sensitivity analyses were conducted to test the robustness of
the results to alternative assumptions about the evaluation
period. The first sensitivity analysis addressed the possibility
that patients who switch from their index PI to a different PI,
non-NRTI fusion inhibitor, or integrase inhibitor in response to
adverse effects may wait until after the switch before they fill a
prescription for a medication used to treat the adverse effect
(e.g., a patient waits a few days to fill a prescription for an
antiemetic after switching from a PI that caused gastrointestinal
adverse effects). For this sensitivity analysis, a 7-day window
after atazanavir or darunavir switches within the evaluation
period was allowed for the identification of medically attended
adverse effects. The second sensitivity analysis addressed theTable 2 – Patient demographics.
Atazanavir prematch (n ¼ 8038)
Patient age (y), mean  SD 42.0  9.0
Patient age category (y), n (%)
18–34 1564 (19.5)
35–44 3352 (41.7)
45–54 2455 (30.5)
55–64 667 (8.3)
Female patients, n (%) 2872 (35.7)
Patient race/ethnicity category, n (%)
Black 3875 (48.2)
Hispanic 683 (8.5)
White 2818 (35.1)
Other 662 (8.2)
Patient insurance plan type, n (%)
Comprehensive 5419 (67.4)
HMO 1563 (19.4)
PPO 4 (0.0)
POS with capitation 943 (11.7)
Unknown 109 (1.4)
Index year, n (%)
2003 1982 (24.7)
2004 2732 (34.0)
2005 1553 (19.3)
2006 384 (4.8)
2007 381 (4.7)
2008 502 (6.2)
2009 393 (4.9)
2010 111 (1.4)
HMO, health maintenance organization; POS, point of service; PPO, prefpossibility that the clinical and health care cost impact of an
adverse effect could extend beyond the date of a switch in
response to an adverse effect (e.g., a patient must remain on
lipid-lowering therapies for several months after switching from
a PI that caused dyslipidemia). For this sensitivity analysis, if a
patient experienced an adverse effect prior to switching from
atazanavir or darunavir in the evaluation period, the entire 6-
month period was used to measure the health care costs
associated with the adverse effect.Results
Study Sample
During the study period, there were 47,555 episodes of PI treat-
ment among 37,247 patients. Sequentially, exclusions were 4,877
without at least two NRTIs in their ART regimen, 1,757 not aged
18 to 64 years, 3,326 without at least one medical claim in the
evaluation period, 9,466 with inadequate baseline continuous
enrollment, 4,561 with inadequate evaluation period continuous
enrollment, and 3,544 with prior exposure to the initiated PI.
Among the remaining 20,024 episodes, 8,038 corresponded to
atazanavir and 616 corresponded to darunavir and these were
included within the propensity score model. The propensity score
models successfully achieved a 3:1 match ratio, matching 1,848
atazanavir-treated patients to all 616 darunavir-treated patients.
The discriminant accuracy of the propensity score models, as
indicated by the area under the receiver operating curve,
was 0.890 among ART-naive patients and 0.873 among ART-
experienced patients. The propensity score analyses achieved
statistical balance, as indicated by a standardized difference of
less than 10, for race, Medicaid state, ART experience, and allAtazanavir postmatch (n ¼ 1848) Darunavir (n ¼ 616)
41.1  9.8 43  9.2
465 (25.2) 111 (18.0)
671 (36.3) 247 (40.1)
559 (30.2) 199 (32.3)
153 (8.3) 59 (9.6)
965 (52.2) 279 (45.3)
1280 (69.3) 410 (66.6)
25 (1.4) 17 (2.8)
374 (20.2) 125 (20.3)
169 (9.1) 64 (10.4)
651 (35.2) 221 (35.9)
660 (35.7) 181 (29.4)
1 (0.1) 0 (0.0)
494 (26.7) 174 (28.2)
42 (2.3) 40 (6.5)
0 (0.0) 0 (0.0)
14 (0.8) 0 (0.0)
457 (24.7) 0 (0.0)
273 (14.8) 32 (5.2)
314 (17.0) 107 (17.4)
407 (22.0) 174 (28.2)
293 (15.9) 218 (35.4)
90 (4.9) 85 (13.8)
erred provider organization.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 1 8 – 4 2 5422included comorbid conditions. Covariates for which statistical
imbalance remained were adjusted in the postmatch multivari-
able analyses.
Table 2 displays patient demographic characteristics for the
unmatched atazanavir cohort and for the matched atazanavir
and darunavir cohorts. After matching, most patients were in the
35 to 44 years of age category, approximately half were men, and
most were of black race/ethnicity.
Table 3 displays clinical characteristics for the unmatched
atazanavir cohort and for the matched atazanavir and darunavir
cohorts. Prior to matching, 83.7% of the atazanavir cohort was
ART experienced; after matching, 91.2% of each cohort was ART
experienced. Tenofovir and emtricitabine were the NRTIs that
were most commonly used as part of the index ART regimen
or during the 6-month baseline period. Darunavir-treated patients
had numerically higher percentages of patients with baseline
medically attended adverse effects.
Incidence and Health Care Costs of Medically Attended
Adverse Effects without Multivariable Adjustment
Table 4 displays the duration of the evaluation period in days and
unadjusted incidence rates and average PPPM health care costs of
medically attended adverse effects during the evaluation period.
Compared with atazanavir-treated patients, darunavir-treatedTable 3 – Patient baseline period clinical characteristics
Atazanavir
prematch
(n ¼ 8038)
ART experienced (nonnaive), n (%) 6731 (83.7)
ARVs included in ART regimen or used during 6-mo baseline period, n (
Ritonavir 6827 (84.9)
NRTIs
Tenofovir 6295 (78.3)
Emtricitabine 3122 (38.8)
Abacavir 2661 (33.1)
Lamivudine 4936 (61.4)
Didanosine 2004 (24.9)
Zidovudine 2710 (33.7)
Stavudine 1232 (15.3)
Zalcitabine 16 (0.2)
Number of three-digit ICD-9-CM
Mean  SD 11.3  8.9
Median 9
Number of unique NDCs
Mean  SD 14.8  8.5
Median 13
Comorbid conditions, n (%)
Hepatitis B 144 (1.8)
Hepatitis C 635 (7.9)
Alcohol or substance abuse 1006 (12.5)
Depression 1055 (13.1)
Any other psychiatric diagnosis 1207 (15.0)
Cognitive impairment 0 (0.0)
Medically attended adverse effects, n (%)
Gastrointestinal 669 (8.3)
Jaundice 6 (0.1)
Lipid abnormalities 477 (5.9)
Diabetes/hyperglycemia 509 (6.3)
Rash 275 (3.4)
ART, antiretroviral therapy; ARV, antiretroviral; ICD-9-CM, International C
national drug code; NRTI, nucleoside reverse transcriptase inhibitor.patients’ incidence rates of medically attended adverse effects
were numerically greater for gastrointestinal, lipid abnormalities,
and rash and numerically lower for diabetes/hyperglycemia
and jaundice. Furthermore, darunavir-treated patients’ average
PPPM health care costs of medically attended adverse effects
were numerically greater for gastrointestinal, numerically lower
for jaundice and diabetes/hyperglycemia, and similar for lipid
abnormalities and rash.
Average PPPM medically attended gastrointestinal and rash
adverse effect health care costs were primarily driven by phar-
macy costs. Approximately 99% of the gastrointestinal pharmacy
costs were for antiemetics (data not shown). Average PPPM
medically attended jaundice, lipid abnormality, and diabetes/
hyperglycemia adverse effect health care costs were primarily
driven by inpatient care.
In the two sensitivity analyses, the results were not substan-
tively changed and were consistent across the two PIs. When
allowing a 7-day window after atazanavir or darunavir switches
for the identification of adverse effects, percentage changes in
the incidence rates of adverse effects per 1000 person-months
ranged from 1% to 8%. When using the entire 6-month period to
measure health care costs associated with the adverse effects
that occurred prior to atazanavir or darunavir switches, the
estimated PPPM costs decreased for acute adverse effects and
increased for chronic adverse effects. The largest observed.
Atazanavir
postmatch
(n ¼ 1848)
Darunavir
(n ¼ 616)
1686 (91.2) 562 (91.2)
%)
1645 (89.0) 608 (98.7)
1495 (80.9) 536 (87.0)
1242 (67.2) 465 (75.5)
571 (30.9) 170 (27.6)
876 (47.4) 208 (33.8)
198 (10.7) 70 (11.4)
567 (30.7) 128 (20.8)
126 (6.8) 22 (3.6)
0 (0.0) 0 (0.0)
13.7  10.2 15.2  10.9
11 12
13.9  8.5 16.1  9.5
12 14
47 (2.5) 22 (3.6)
184 (10.0) 62 (10.1)
329 (17.8) 118 (19.2)
236 (12.8) 74 (12.0)
308 (16.7) 111 (18.0)
0 (0.0) 0 (0.0)
172 (9.3) 68 (11.0)
2 (0.1) 2 (0.3)
119 (6.4) 68 (11.0)
144 (7.8) 62 (10.1)
72 (3.9) 26 (4.2)
lassification of Diseases, Ninth Revision, Clinical Modification; NDC,
Table 4 – Unadjusted incidence rates and PPPM
health care costs of medically attended (ICD-9-
CM–coded or treated) adverse effects during the
evaluation period.
Atazanavir
(n ¼ 1848)
Darunavir
(n ¼ 616)
Duration of evaluation period (d)
Mean  SD 159  50 151  60
Median 180 180
Gastrointestinal
Number at risk, n (%) 1848 (100.0%) 616 (100.0%)
Incidence rate (per 1000
person-months)
42.55 59.96
PPPM total health care
costs, mean  SD
$38  $387 $73  $382
Inpatient costs $13  $349 $17  $203
Outpatient costs $3  $23 $7  $52
Pharmacy costs $21  $144 $49  $298
Jaundice
Number at risk, n (%) 1848 (100.0) 616 (100.0)
Incidence rate (per 1000
person-months)
1.12 0.32
PPPM total health care
costs, mean  SD
$14  $544 $0  $4
Inpatient costs $14  $544 $0  $4
Outpatient costs $0  $6 $0  $1
Lipid abnormalities
Number at risk, n (%) 1729 (93.6) 548 (89.0)
Incidence rate (per 1000
person-months)
17.49 27.31
PPPM total health care
costs, mean  SD
$28  $396 $27  $297
Inpatient costs $21  $393 $13  $258
Outpatient costs $2  $18 $6  $43
Pharmacy costs $5  $26 $8  $36
Diabetes/hyperglycemia
Number at risk, n (%) 1704 (92.2) 554 (89.9)
Incidence rate (per 1000
person-months)
8.4 7.67
PPPM total health care
costs, mean  SD
$96  $1253 $62  $518
Inpatient costs $78  $1232 $35  $459
Outpatient costs $13  $108 $19  $125
Pharmacy costs $6  $35 $8  $48
Rash
Number at risk, n (%) 1848 (100.0%) 616 (100.0%)
Incidence rate (per 1000
person-months)
87.11 111.03
PPPM total health care
costs, mean  SD
$6  $80 $5  $25
Inpatient costs $2  $71 $0  $0
Outpatient costs $1  $31 $0  $3
Pharmacy costs $3  $11 $4  $24
All-cause health care costs, mean  SD
PPPM total health care costs $3879  $6635 $5354  $8127
Inpatient costs $1257  $6174 $1520  $6875
Outpatient costs $546  $1103 $634  $1187
Pharmacy costs $2076  $1829 $3200  $4053
ICD-9-CM, International Classification of Diseases, Ninth Revision,
Clinical Modification; PPPM, per-patient-per-month.
* All-cause health care costs are health care costs incurred for all
inpatient medical, outpatient medical, and outpatient prescription
claims during the evaluation period and are not limited to
medically attended adverse effects.
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estimated PPPM health care cost decreased from $14 to $2.
Incidence and Health Care Costs of Medically Attended
Adverse Effects with Multivariable Adjustment
Table 5 displays the postmatch multivariable-adjusted hazard
ratios and PPPM health care cost differences for medically
attended adverse effects during the evaluation period.
Compared with atazanavir-treated patients, darunavir-treated
patients had significantly greater hazards of medically attended
gastrointestinal adverse effects, insignificantly greater hazards of
medically attended lipid abnormalities and rash adverse effects,
and insignificantly lower hazards of medically attended diabetes/
hyperglycemia adverse effects.
Compared with atazanavir-treated patients, darunavir-treated
patients had significantly greater PPPM all-cause health care
costs and insignificantly greater ($0 difference in the case of
rash) PPPM medically attended adverse effect health care costs
for all the specific medically attended adverse effects.
Too few instances of jaundice (11 in atazanavir and 1 in
darunavir) occurred to support multivariable modeling. No multi-
variable adjustment was conducted for the sensitivity analyses.Discussion
This is the first study to compare the incidence and health care
costs of medically attended adverse effects in U.S. Medicaid
patients receiving atazanavir- or darunavir-based ART. Therefore,
these data provide valuable insights into the real-world experi-
ence of a large segment of the U.S. HIV population.
One of the reasons for studying gastrointestinal adverse
effects currently is that to date, studies comparing darunavir
with atazanavir with regard to this adverse effect have been
equivocal. In the CASTLE (comparison of atazanavir/ritonavir in
naive subjects in combination with tenofovir-emtricitabine ver-
sus lopinavir/ritonavir in combination with tenofovir-emtricita-
bine to assess safety and efficacy), ARTEMIS (AntiRetroviral
Therapy with TMC114 ExaMined In naı¨ve Subjects), BMS-045
(Bristol Myers Squibb Study 045), and TITAN (TMC114/r In Treat-
ment-experienced pAtients Naive to lopinavir) trials, atazanavir
and darunavir were separately demonstrated to have favorable
gastrointestinal tolerability compared with lopinavir in
treatment-naive patients and treatment-experienced patients,
respectively [19]. In each of the trials, the relative risk of grades
2 to 4 diarrhea and nausea for atazanavir tended to be lower than
that for darunavir, when both were compared with lopinavir.
However, across-trial differences in procedures and populations
limit the ability to draw a meaningful conclusion on the com-
parative gastrointestinal tolerability of atazanavir and darunavir.
In a randomized exploratory study of the metabolic effects of
darunavir/ritonavir and atazanavir/ritonavir in treatment-naive
HIV patients over 48 weeks, one darunavir-treated patient and no
atazanavir-treated patient experienced grades 2 to 4 diarrhea
related to treatment [20]. This study, however, was small (65
subjects), with meaningful differences in baseline characteristics
between the treatment groups, again limiting the ability to draw
a meaningful conclusion. Therefore, the current real-world data
that show a significantly higher hazard ratio of medically
attended gastrointestinal adverse effects for darunavir compared
with atazanavir are of interest, particularly because gastrointest-
inal intolerance is a known risk factor for treatment failure [21].
Medically attended jaundice adverse effects were the least
frequently occurring of the examined adverse effects. While the
small number of events that occurred (12 in total) precluded
multivariable analysis, the descriptive differences in the number
Table 5 – Postmatch multivariable-adjusted hazard ratios and PPPM health care cost differences for medically
attended (ICD-9-CM–coded or treated) adverse effects during the evaluation period.
Hazard ratio*
(atazanavir ¼ reference)
PPPM health care cost difference*
(darunavir  atazanavir)
Gastrointestinal 1.251 P ¼ 0.043 $43 P ¼ 0.132
Lipid abnormalities 1.375 P ¼ 0.072 $3 P ¼ 0.879
Diabetes/hyperglycemia 0.843 P ¼ 0.552 $13 P ¼ 0.693
Rash 1.108 P ¼ 0.233 $0 P ¼ 0.760
All-causey health care costs NA NA $1086 Po 0.001
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NA, not available/applicable; PPPM, per-patient-per-
month.
* The multivariable models adjusted for covariates within the propensity score model that lacked postmatch statistical balance; the baseline
presence of each specific adverse effect was also included in its respective individual model. For the two-part health care cost models
(gastrointestinal, diabetes/hyperglycemia, and rash), P values were developed by using bootstrapping with 500 repetitions. Too few instances
of jaundice (11 in atazanavir and 1 in darunavir) occurred to support multivariable modeling.
y All-cause health care costs are health care costs incurred for all inpatient medical, outpatient medical, and outpatient prescription claims
during the evaluation period and are not limited to medically attended adverse effects.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 1 8 – 4 2 5424of patients with medically attended jaundice adverse effects
favored darunavir. The low incidence rates observed in the
present study are consistent with results from prior clinical trials
showing that jaundice is relatively uncommon with both ataza-
navir/ritonavir and darunavir/ritonavir treatment [22,23]. The
PPPM health care costs associated with medically attended
jaundice were relatively low in atazanavir-treated patients, ran-
ging from $2 in the sensitivity analyses to $14 in the primary
analyses. This is likely due to the nature of jaundice associated
with atazanavir that occurs in some patients who have
atazanavir-associated hyperbilirubinemia. This hyperbilirubine-
mia is not associated with hepatitis and reverses upon disconti-
nuation of atazanavir without any additional treatment [24].
There were no differences between atazanavir and darunavir
for all other studied adverse effects. While there was a numeri-
cally lower hazard of medically attended diabetes/hyperglycemia
adverse effects, this was not significantly different and was
inconsistent with numerically higher adjusted health care costs
for medically attended diabetes/hyperglycemia in darunavir-
treated patients.
The present study also found that darunavir-treated patients
incurred significantly higher all-cause health care costs than did
atazanavir-treated patients, a result of increased costs across all
settings of care (inpatient, outpatient, and pharmacy), with the
majority of the difference being driven by pharmacy costs. These
pharmacy costs are not strictly related to the management of HIV
but also include costs for all outpatient prescriptions used to
manage comorbidities, adverse effects, and any other medical
needs that are treated with pharmacotherapy. This $1086 PPPM
difference translated into an annual health care cost difference of
approximately $13,000 per patient. Although the present study
did not explore the detailed drivers of these differences in costs,
future research could help to elucidate this matter by examining
underlying differences in the services utilized in each setting of
care, the diagnosis coding recorded for those services, and the
various classes of medications that patients used. Given the
substantial magnitude of the all-cause cost differences, such
additional research is warranted.
This study was subject to limitations. First, administrative
claims data are not collected for research purposes and may be
subject to errors in diagnostic coding. Second, this study speci-
fically examined medically attended adverse effects and there-
fore less severe adverse effects, specifically those for which the
severity did not motivate medical attendance, would not have
been captured. Third, because we defined ART experience as
having prescription claims for ART during the 6-month baselineperiod, we cannot rule out the possibility of misclassification for
those patients who may have had claims for ART more than 6
months prior to their index date. Fourth, because this database
contains data for patients covered through Medicaid within 15
states, the findings may not be generalizable to the whole U.S.
HIV population. Fifth, because this study used an observational
study design, we cannot exclude the possibility of residual
confounding from unmeasured factors. The most relevant
unmeasured factors in this study are clinical data, such as CD4
and viral load values or history of AIDS, which are not available in
the data used for this study. These factors are likely to correlate
with patients’ economic and clinical outcomes. If atazanavir or
darunavir is prescribed in a manner that systematically favors
patients with a history of AIDS or low CD4 and viral load values
beyond what was accounted for through stratification of the
propensity score models by ART experience, the present study
results could be confounded by such prescribing behavior. As
such, we can establish associations, but not causal relationships,
between treatments and outcomes.
Because this study is one of the first of its kind, future
research is warranted to corroborate these findings and advance
the understanding of the adverse effects of atazanavir and
darunavir in various populations. Within the present study, most
(91.2%) patients were ART experienced. Because these agents
have become more frequently prescribed in ART-naive patients,
future studies that include such patients are needed to address
these matters in this important segment of the HIV population.Conclusions
In the present study of the incidence and health care costs of
medically attended adverse effects in Medicaid patients receiving
routine HIV care, atazanavir-treated patients had significantly
fewer instances of medically attended gastrointestinal issues and
more instances of jaundice and incurred significantly lower
health care costs than did darunavir-treated patients. Source of
financial support: Bristol-Myers Squibb sponsored this study.
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